New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 9, 2014
14:27 EDTVRXJublia could become Valeant's biggest product, says Jefferies
After Valeant announced FDA approval for Jublia, on schedule and as expected, Jefferies said the product targets an underserved market and could become the company's biggest drug. Jefferies sees peak worldwide sales for Jublia of $400M-$500M, but adds that its forecast could be conservative. The firm maintains its Buy rating and $154 price target on Valeant.
News For VRX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
December 19, 2014
08:05 EDTVRXValeant outlook has improved, says RBC Capital
Subscribe for More Information
December 17, 2014
10:53 EDTVRXAckman says 'will take hard look' at Valeant shares after restrictions end
Subscribe for More Information
December 9, 2014
09:31 EDTVRXZoetis drops after report of Valeant abandoning growth by acquisitions strategy
Subscribe for More Information
06:39 EDTVRXValeant to abandon growth by acquisitions strategy, Reuters says
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use